National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lutetium (177Lu) Oxodotreotide (Lutathera®) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.


NCPE Assessment Process Complete
Rapid review commissioned 23/10/2018
Rapid review completed 16/11/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE 21/11/2018
Pre-submission consultation with Applicant 17/12/2018
Submission received from Applicant 23/05/2019
HTA assessment commenced 12/08/2019
Preliminary review sent to Applicant 04/10/2019
NCPE assessment re-commenced 01/11/2019
Preliminary review #2 sent to Applicant 22/11/2019
NCPE assessment re-commenced 02/12/2019
Factual Accuracy sent to Applicant 10/01/2020
NCPE assessment re-commenced 20/01/2020
NCPE assessment completed 07/02/2020
NCPE assessment outcome The NCPE recommends that lutetium (177Lu) oxodotreotide (Lutathera®) not be considered for reimbursement*.

Technical Summary

Plain English Summary


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.